<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03092102</url>
  </required_header>
  <id_info>
    <org_study_id>PCD-DHEC585-16-001</org_study_id>
    <nct_id>NCT03092102</nct_id>
  </id_info>
  <brief_title>The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects</brief_title>
  <official_title>A Phase I, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunshine Lake Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunshine Lake Pharma Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Safety, Tolerability and Pharmacokinetic Study of idiopathic pulmonary fibrosis treatment&#xD;
      drug HEC585 in Healthy Male and Female Subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a double-blind, placebo-controlled, single, and multiple oral dose study&#xD;
      conducted in 2 parts.&#xD;
&#xD;
      Part A will comprise a single-dose, sequential-group study incorporating a food effect&#xD;
      evaluation. Up to 48 subjects will be studied in up to 6 groups (Groups A1 to A6), with each&#xD;
      group consisting of 8 subjects. Each subject will participate in 1 treatment period only and&#xD;
      reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144&#xD;
      hours postdose), except for Group A3, which will participate in a second treatment period for&#xD;
      a food effect evaluation. Each subject in Group A3 will participate in 2 treatment periods&#xD;
      separated by a minimum of 7 days. Dosing of subjects in the fed state in Group A3 can&#xD;
      commence after review of the safety data from Group A4.&#xD;
&#xD;
      Part B will comprise a multiple-dose, sequential-group study. Up to 36 subjects will be&#xD;
      studied in up to 3 groups (Groups B1 to B3), with each group consisting of 12 subjects. Part&#xD;
      B of the study may start after completion of Group A5, at a dose equal or less than given in&#xD;
      Groups A1 to A3.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2017</start_date>
  <completion_date type="Actual">February 25, 2019</completion_date>
  <primary_completion_date type="Actual">February 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h</time_frame>
    <description>Geometric Mean of Maximum Observed Plasma Concentration of HEC585</description>
  </primary_outcome>
  <primary_outcome>
    <measure>(AUC0-∞）</measure>
    <time_frame>Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120,144,and 216 h</time_frame>
    <description>area under the plasma concentration-time curve (AUC) from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax</measure>
    <time_frame>Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h</time_frame>
    <description>time of the maximum observed plasma concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz/F</measure>
    <time_frame>Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120,144,and 216 h</time_frame>
    <description>apparent volume of distribution</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t½</measure>
    <time_frame>Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h</time_frame>
    <description>apparent terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F</measure>
    <time_frame>Predose, and 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 36, 48, 72, 96, 120, 144,and 216 h</time_frame>
    <description>apparent oral clearance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>From baseline to 7 days</time_frame>
    <description>To assess the safety and tolerability of 7 days therapy.</description>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>A single dose HEC585（A1）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A single dose HEC585（A2）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A single dose HEC585/FE（A3）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule&#xD;
Treatment Period 1：No food prior to dosing；Treatment Period 2：High-fat meal prior to dosing</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A single dose HEC585（A4）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A single dose HEC585（A5）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A single dose HEC585（A6）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A single dose HEC585（A7）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A single dose HEC585（A8）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses HEC585（B1）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses HEC585（B2）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses HEC585（B3）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses HEC585（B4）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses HEC585（B5）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple doses HEC585（B6）</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: HEC585 Capsule&#xD;
Drug: HEC585-matching placebo Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HEC585</intervention_name>
    <description>HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.</description>
    <arm_group_label>A single dose HEC585/FE（A3）</arm_group_label>
    <arm_group_label>A single dose HEC585（A1）</arm_group_label>
    <arm_group_label>A single dose HEC585（A2）</arm_group_label>
    <arm_group_label>A single dose HEC585（A4）</arm_group_label>
    <arm_group_label>A single dose HEC585（A5）</arm_group_label>
    <arm_group_label>A single dose HEC585（A6）</arm_group_label>
    <arm_group_label>A single dose HEC585（A7）</arm_group_label>
    <arm_group_label>A single dose HEC585（A8）</arm_group_label>
    <arm_group_label>Multiple doses HEC585（B1）</arm_group_label>
    <arm_group_label>Multiple doses HEC585（B2）</arm_group_label>
    <arm_group_label>Multiple doses HEC585（B3）</arm_group_label>
    <arm_group_label>Multiple doses HEC585（B4）</arm_group_label>
    <arm_group_label>Multiple doses HEC585（B5）</arm_group_label>
    <arm_group_label>Multiple doses HEC585（B6）</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females, of any race, between 18 and 60 years of age, inclusive, at&#xD;
             Screening.&#xD;
&#xD;
          2. Body mass index between 18.0 and 32.0 kg/m2, inclusive, at Screening.&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12-lead ECG, vital sign measurements, and clinical laboratory&#xD;
             evaluations (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is&#xD;
             not acceptable) at Screening and/or Check-in as assessed by the Investigator (or&#xD;
             designee).&#xD;
&#xD;
          4. Females will be nonpregnant and nonlactating. Females of childbearing potential and&#xD;
             male subjects will agree to use contraception.&#xD;
&#xD;
          5. Able to comprehend and willing to sign an informed consent form (ICF) and to abide by&#xD;
             the study restrictions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as&#xD;
             determined by the Investigator (or designee).&#xD;
&#xD;
          2. History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the Investigator (or designee).&#xD;
&#xD;
          3. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs (uncomplicated appendectomy&#xD;
             and hernia repair will be allowed).&#xD;
&#xD;
          4. History of alcoholism or drug/chemical abuse within 2 years prior to Check-in.&#xD;
&#xD;
          5. Alcohol consumption of &gt; 21 units per week for males and &gt; 14 units for females. One&#xD;
             unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL&#xD;
             wine), or a positive alcohol breath test at Check-in.&#xD;
&#xD;
          6. Positive urine drugs of abuse screen including cotinine at Screening or Check-in.&#xD;
&#xD;
          7. Positive hepatitis B surface antigen, hepatitis C virus antibody and/or positive human&#xD;
             immunodeficiency virus (HIV) test (Appendix 3).&#xD;
&#xD;
          8. Absolute lymphocyte count below the lower limit of normal which can be confirmed by&#xD;
             repeat.&#xD;
&#xD;
          9. Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 30 days or 5 half-lives (if known), whichever is&#xD;
             longer, prior to Check-in.&#xD;
&#xD;
         10. Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's Wort, within 30 days prior&#xD;
             to Check-in, unless deemed acceptable by the Investigator (or designee). Strong CYP3A&#xD;
             inhibitors and inducers should be avoided.&#xD;
&#xD;
         11. Use or intend to use any prescription medications/products, within 14 days prior to&#xD;
             Check-in, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
         12. Use or intend to use any nonprescription medications/products including vitamins,&#xD;
             minerals, and phytotherapeutic/herbal/plant-derived preparations within 7 days prior&#xD;
             to Check-in, unless deemed acceptable by the Investigator (or designee).&#xD;
&#xD;
         13. Use of tobacco- or nicotine-containing products within 3 months prior to Check-in.&#xD;
&#xD;
         14. Consumption of foods and beverages containing poppy seeds, grapefruit, or Seville&#xD;
             oranges within 7 days prior to Check-in, consumption of caffeine-containing foods and&#xD;
             beverages within 72 hours prior to Check-in, or consumption of alcohol within 48 hours&#xD;
             prior to Check-in.&#xD;
&#xD;
         15. Receipt of blood products within 2 months prior to Check-in.&#xD;
&#xD;
         16. Donation of blood from 56 days prior to Screening, plasma from 2 weeks prior to&#xD;
             Screening, or platelets from 6 weeks prior to Screening.&#xD;
&#xD;
         17. Poor peripheral venous access.&#xD;
&#xD;
         18. Have previously completed or withdrawn from this study, and have previously received&#xD;
             the investigational product.&#xD;
&#xD;
         19. Subjects who, in the opinion of the Investigator (or designee), should not participate&#xD;
             in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Covance Clinical Research Unit, Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>35756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 21, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 27, 2017</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

